bs-2669R-PE [Conjugated Primary Antibody]
NFATc2(Ser326) Polyclonal Antibody, PE Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: NFATc2 Ser326

Modification Site: Ser326

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 4773

Source: KLH conjugated synthetic phosphopeptide derived from human NFATc2 around the phosphorylation site of Ser326

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Nuclear factor of activated T cells (NFAT) is a family of transcription factors implicated in multiple biological processes including cytokine gene expression, cardiac hypertrophy and adipocyte differentiation. NFAT1 (also known as NFATc2 or NFATp) is a member of this family that is regulated by the calcium-dependent phosphatase calcineurin. When calcineurin is activated by calcium it dephosphorylates multiple residues in the regulatory domain of NFAT1, leading to its translocation to the nucleus and activation of its transcriptional activity. Once in the nucleus, NFAT proteins act synergistically with the AP-1 transcription factor complex to regulate the expression of multiple genes. Serine 54 in mouse NFAT1 has been shown to be important in the regulation of its transcriptional activity.

Conjugation: PE

Excitation/ Emission: 496,564nm/578nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
FCM(1:20-100)

Predicted Molecular Weight: 102


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog
Cow
Pig
Horse
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Marunouchi Tetsuro. et al. Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways. J Cardiovasc Pharm. 2021 Jun;77(6):822-829Read more>>
  • Tetsuro Marunouchi. et al. Simvastatin attenuates the c-Raf/Erk and calcineurin-NFATc2 pathways via inhibition of Hsp90 activity during the development of heart failure.. J PHARMACOL SCI. 2022 NovRead more>>
VALIDATION IMAGES